MK 7762
Alternative Names: MK-7762; TBD-09Latest Information Update: 20 Apr 2026
At a glance
- Originator Merck & Co
- Developer Gates Medical Research Institute; Merck & Co
- Class Amines; Antibacterials; Antituberculars; Carbamates; Chlorinated hydrocarbons; Cyclohexanes; Ethanolamines; Fluorobenzenes; Methyl ethers; Nitriles; Oxazolidinones; Pyrans; Pyridines; Thiamorpholines; Thiazoles
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Tuberculosis
Most Recent Events
- 13 Apr 2026 Gates Medical Research Institute in collaboration with IQVIA RDS plans a phase II trial for Pulmonary tuberculosis (Newly diagnosed, Combination therapy) in South Africa in April 2026 (NCT07525427)
- 13 Aug 2025 Chemical structure information added.
- 31 Jul 2025 Gates Medical Research Institute plans a phase I trial in healthy volunteers (PO) in September 2025 (NCT07094932)